vs
CytomX Therapeutics, Inc.（CTMX）与FIDELITY D & D BANCORP INC（FDBC）财务数据对比。点击上方公司名可切换其他公司
FIDELITY D & D BANCORP INC的季度营收约是CytomX Therapeutics, Inc.的1.3倍（$24.4M vs $18.7M），FIDELITY D & D BANCORP INC净利率更高（32.5% vs -0.8%，领先33.4%），FIDELITY D & D BANCORP INC同比增速更快（15.0% vs -25.7%），FIDELITY D & D BANCORP INC自由现金流更多（$24.8M vs $-15.8M），过去两年FIDELITY D & D BANCORP INC的营收复合增速更高（11.8% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Fidelity D & D Bancorp Inc是一家总部位于美国的地区性银行控股公司，主要在宾夕法尼亚州东北部开展业务，为个人消费者、小微企业及当地社区客户提供存款账户、消费及商业贷款、抵押贷款、财富管理等综合零售及商业银行服务。
CTMX vs FDBC — 直观对比
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $24.4M |
| 净利润 | $-154.0K | $7.9M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 37.7% |
| 净利率 | -0.8% | 32.5% |
| 营收同比 | -25.7% | 15.0% |
| 净利润同比 | 97.6% | 36.1% |
| 每股收益（稀释后） | — | $1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $24.4M | ||
| Q3 25 | — | $23.5M | ||
| Q2 25 | $18.7M | $23.3M | ||
| Q1 25 | $50.9M | $22.0M | ||
| Q4 24 | $38.1M | $21.2M | ||
| Q3 24 | $33.4M | $20.4M | ||
| Q2 24 | $25.1M | $19.7M | ||
| Q1 24 | $41.5M | $19.5M |
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.3M | ||
| Q2 25 | $-154.0K | $6.9M | ||
| Q1 25 | $23.5M | $6.0M | ||
| Q4 24 | $18.9M | $5.8M | ||
| Q3 24 | $5.7M | $5.0M | ||
| Q2 24 | $-6.5M | $4.9M | ||
| Q1 24 | $13.8M | $5.1M |
| Q4 25 | — | 37.7% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | -6.9% | 35.5% | ||
| Q1 25 | 44.4% | 32.2% | ||
| Q4 24 | 46.4% | 31.4% | ||
| Q3 24 | 12.3% | 28.2% | ||
| Q2 24 | -33.7% | 28.9% | ||
| Q1 24 | 28.1% | 29.5% |
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | -0.8% | 29.7% | ||
| Q1 25 | 46.2% | 27.2% | ||
| Q4 24 | 49.6% | 27.5% | ||
| Q3 24 | 17.2% | 24.3% | ||
| Q2 24 | -26.0% | 25.0% | ||
| Q1 24 | 33.3% | 25.9% |
| Q4 25 | — | $1.29 | ||
| Q3 25 | — | $1.27 | ||
| Q2 25 | — | $1.27 | ||
| Q1 25 | — | $1.03 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | — | $0.86 | ||
| Q2 24 | — | $0.86 | ||
| Q1 24 | — | $0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $148.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $238.9M |
| 总资产 | $175.1M | $2.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $148.1M | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | $49.0M | $165.5M | ||
| Q1 25 | $47.6M | $211.2M | ||
| Q4 24 | $38.1M | $83.4M | ||
| Q3 24 | $40.6M | $120.2M | ||
| Q2 24 | $43.2M | $78.1M | ||
| Q1 24 | $36.2M | $72.7M |
| Q4 25 | — | $238.9M | ||
| Q3 25 | — | $229.2M | ||
| Q2 25 | $119.9M | $217.9M | ||
| Q1 25 | $25.0M | $211.7M | ||
| Q4 24 | $-456.0K | $204.0M | ||
| Q3 24 | $-23.5M | $207.3M | ||
| Q2 24 | $-31.2M | $195.7M | ||
| Q1 24 | $-31.7M | $191.6M |
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $175.1M | $2.7B | ||
| Q1 25 | $98.5M | $2.7B | ||
| Q4 24 | $120.5M | $2.6B | ||
| Q3 24 | $139.0M | $2.6B | ||
| Q2 24 | $159.2M | $2.5B | ||
| Q1 24 | $184.7M | $2.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $42.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $24.8M |
| 自由现金流率自由现金流/营收 | -84.6% | 101.7% |
| 资本支出强度资本支出/营收 | 0.1% | 71.9% |
| 现金转化率经营现金流/净利润 | — | 5.34× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $45.4M |
8季度趋势，按日历期对齐
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $8.4M | ||
| Q2 25 | $-15.8M | $12.6M | ||
| Q1 25 | $-21.0M | $11.7M | ||
| Q4 24 | $-19.9M | $29.6M | ||
| Q3 24 | $-20.7M | $9.1M | ||
| Q2 24 | $-19.5M | $8.7M | ||
| Q1 24 | $-26.0M | $5.3M |
| Q4 25 | — | $24.8M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $-15.8M | $6.9M | ||
| Q1 25 | $-21.2M | $11.5M | ||
| Q4 24 | $-20.0M | $24.9M | ||
| Q3 24 | $-20.7M | $7.8M | ||
| Q2 24 | $-19.6M | $7.2M | ||
| Q1 24 | $-26.2M | $4.0M |
| Q4 25 | — | 101.7% | ||
| Q3 25 | — | 9.3% | ||
| Q2 25 | -84.6% | 29.6% | ||
| Q1 25 | -41.6% | 52.3% | ||
| Q4 24 | -52.5% | 117.3% | ||
| Q3 24 | -62.1% | 38.1% | ||
| Q2 24 | -78.2% | 36.6% | ||
| Q1 24 | -63.1% | 20.7% |
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | 0.1% | 24.4% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.2% | 22.0% | ||
| Q3 24 | 0.1% | 6.3% | ||
| Q2 24 | 0.4% | 7.5% | ||
| Q1 24 | 0.3% | 6.7% |
| Q4 25 | — | 5.34× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.82× | ||
| Q1 25 | -0.89× | 1.95× | ||
| Q4 24 | -1.05× | 5.07× | ||
| Q3 24 | -3.61× | 1.83× | ||
| Q2 24 | — | 1.76× | ||
| Q1 24 | -1.89× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FDBC
暂无分部数据
